Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.9% at HKD 24.1, with a trading volume of HKD 57.28 million, following the announcement of positive results from the SACHI III study published in The Lancet [1] Group 1: Study Announcement - The SACHI III study results involve a combination therapy of Savolitinib (赛沃替尼) and Osimertinib (奥希替尼) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR tyrosine kinase inhibitor (TKI) treatment [1] - Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, and commercialized by AstraZeneca [1] - Osimertinib is an irreversible third-generation EGFR TKI [1] Group 2: Regulatory Approval - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to receive approval in China by June 2025 [1]

Group 1 - The provincial government is actively seeking input on the "Government Work Report (Draft for Comments)" and the "14th Five-Year Plan" from various stakeholders, including democratic parties, business associations, and non-partisan individuals [1][2] - The provincial government emphasizes the importance of collaboration with stakeholders to enhance democratic decision-making and improve the government's ability to address public concerns [1][2] - Business leaders from companies such as Jiangsu Guoxin Group, Jiangsu Expressway, AstraZeneca, and others provided suggestions to support high-quality development and modernization efforts in Jiangsu [2] Group 2 - The provincial government aims to strengthen communication and cooperation with representatives and committee members to better reflect public sentiment and contribute to scientific and democratic decision-making [2] - The government plans to focus on enhancing resource allocation for enterprises, supporting quality enterprises in expanding production, and fostering innovation in key industries [2]

Market Overview - The US stock market closed lower, with major technology stocks leading the decline as traders processed the latest batch of bank earnings and geopolitical risks loomed over market sentiment [1][8] - The Dow Jones Industrial Average fell by 158.38 points (0.32%) to 49,033.61, the Nasdaq dropped by 333.36 points (1.41%) to 23,376.51, and the S&P 500 decreased by 56.64 points (0.81%) to 6,907.10 [3][10] Banking Sector Performance - Wells Fargo's stock declined by 5.6% after reporting fourth-quarter revenue below expectations, while Bank of America fell by 3.6% despite exceeding expectations in trading revenue due to cost concerns [3][10] - In contrast, Citigroup reported fourth-quarter results that surpassed expectations [3] - The financial sector was the worst-performing industry, with JPMorgan's stock dropping over 4% due to disappointing investment banking expenses [3][10] Economic Data and Federal Reserve Outlook - US retail sales for November increased by 0.6%, the highest since July, surpassing market expectations of 0.4% [5][12] - Analysts predict that these retail sales figures may not impact Federal Reserve policy, as the Fed had already cut rates in December without this data [12] - The Federal Reserve is expected to maintain interest rates steady for the next six months, with potential cuts in the second half of 2026 [5][12] Geopolitical Factors - The market is experiencing heightened uncertainty due to geopolitical risks, particularly regarding the US's potential intervention in Iran [1][12] - Analysts noted that the uncertainty surrounding Iran has made it difficult to assess cross-market transmission paths [12] Individual Company Updates - Rivian is recalling over 19,000 electric vehicles, leading to a downgrade by UBS to "sell" [13] - Intel's stock rose following indications that Apple has invested in the company [14] - Honeywell's quantum computing division, Quantinuum, plans to file for an IPO [15] - AstraZeneca has acquired Modella AI to accelerate its cancer drug development [16] - Bilibili reported that its advertising revenue has grown over 20% for 11 consecutive quarters [17]

Core Viewpoint - The results of the SACHI III study, which evaluates the combination therapy of savolitinib and osimertinib for treating EGFR mutation-positive non-small cell lung cancer patients with MET amplification, have been published in The Lancet, indicating significant clinical benefits [1][2]. Group 1: Study Overview - The SACHI study focuses on the combination of savolitinib (a potent MET TKI) and osimertinib (a third-generation EGFR TKI) for patients who have progressed after first-line EGFR TKI treatment [1]. - The combination therapy has been approved in China for use starting June 2025 based on the data from the SACHI study [1]. Group 2: Clinical Implications - The data from the SACHI study provides strong evidence that the combination therapy significantly improves treatment outcomes for patients with MET amplification and EGFR mutations [2]. - The study highlights the ability of the combination therapy to address MET amplification, a key resistance mechanism, offering clinically meaningful improvements for challenging patient populations [2]. - Notably, consistent efficacy was observed in patients who had previously received third-generation EGFR TKI treatment, indicating the therapy's potential for broader application [2].

Market Overview - On January 13, US stock markets closed lower across the board, with the financial sector experiencing significant declines, impacting overall market performance [1][4][6] - The Dow Jones Industrial Average fell by 0.8% to close at 49,191.99 points, while the S&P 500 and Nasdaq indices dropped by 0.19% and 0.1%, closing at 6,963.74 and 23,709.87 points respectively [4][6] Financial Sector Performance - The financial sector saw a substantial drop, led by JPMorgan Chase, which fell over 4%. Other major financial stocks like Morgan Stanley, Goldman Sachs, Citigroup, Bank of America, and Wells Fargo also experienced declines of over 1% [6][7] - Visa's stock dropped more than 4%, with an intraday decline exceeding 5% [6] Technology Sector Performance - Major tech stocks showed mixed results, with Google rising over 1% while companies like Meta, Amazon, and Microsoft fell by more than 1%. Nvidia and Apple had gains of less than 1% [8] - The Philadelphia Semiconductor Index increased by 0.95%, reaching a new historical high, with notable gains from Intel (over 7%) and AMD (over 6%) [8] Energy Sector Performance - Energy stocks collectively rose, with ExxonMobil increasing by nearly 2% and other companies like Schlumberger and Occidental Petroleum rising over 1% [9] Precious Metals Market - The international silver price reached a new historical high, surpassing $89 per ounce, with an increase of over 2% on January 13. Since the beginning of 2026, the price has risen by more than 20% in less than 10 trading days [14][15] Chinese Concept Stocks - Chinese concept stocks generally declined, with the Nasdaq Golden Dragon China Index dropping by 1.86%. Notable declines included Brain Rebirth (over 26%) and WeRide (over 10%) [12][13] - However, some stocks like Canadian Solar and BeiGene saw gains of over 5% [13]

Group 1: Market Performance - The Dow Jones and S&P 500 indices both reached all-time highs, with the Dow closing at 49,590.2 points and the S&P 500 at 6,977.27 points, reflecting increases of 0.17% and 0.16% respectively [6][7]. - The Nasdaq also saw a rise, closing up 0.26% at 23,733.9 points [7]. Group 2: Walmart's Performance - Retail giant Walmart's stock rose by 3%, reaching a record high of $117.97 per share, with a market capitalization of $940.2 billion [10]. - Walmart will replace AstraZeneca in the Nasdaq 100 index, effective January 20, 2026 [13]. Group 3: Chinese Stocks Performance - Chinese stocks performed strongly, with the Nasdaq Golden Dragon China Index increasing by 4.26%. Alibaba led the gains with a surge of over 10%, marking its largest increase since August 29 of the previous year [15]. - Other notable performers included Bilibili, XPeng Motors, and Baidu, which saw increases of over 8%, 8.44%, and 6.07% respectively [15][16]. Group 4: Precious Metals - Gold and silver prices surged, with gold reaching a historical high of $4,640.50 per ounce during trading before settling at $4,596.6, a decrease of 0.39% [18][19]. - Silver also experienced significant movement, with prices reaching $84.25 per ounce, down 0.99% from earlier highs [18][19].

Core Insights - Walmart (WMT.US) shares rose by 3% to a record high of $117.97, with a total market capitalization of $940.24 billion [1] - Walmart will replace AstraZeneca in the Nasdaq-100 index, with the adjustment effective on January 20, 2026 [1] - Walmart and Google announced a shift from traditional web or app searches to AI-driven business models, indicating a significant transformation in the retail industry [1]

Group 1 - Walmart, the largest retailer in the U.S., saw its stock rise by 3% to a record high of $117.97, with a total market capitalization of $94.0241 billion [1] - Walmart will replace AstraZeneca in the Nasdaq-100 index, with the adjustment taking effect on January 20, 2026 [1] - Walmart and Google announced a joint statement indicating a transition from traditional web or app searches to AI-driven business models, marking a significant change in the retail industry [1]

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, with a focus on AI-enabled strategic upgrades in pharmaceutical manufacturing [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a 5.6% increase from December 29, 2025, to January 9, 2026, outperforming the Wind All A index (4.76%) and the CSI 300 index (2.18%). Key segments leading this growth include hospitals (12.95%), medical research outsourcing (9.25%), and medical devices (7.96%) [2][7]. - The report highlights the rapid development of AI in healthcare, emphasizing the government's initiative to foster AI in drug development, supply chain management, surgical robotics, and intelligent diagnostic systems by 2027. This initiative aims to cultivate 2-3 leading ecological enterprises and a number of specialized companies [2][11]. - The upcoming JPM Healthcare Conference from January 12 to 15, 2026, is expected to boost the sentiment in the innovative drug sector, with over 500 listed companies and thousands of startups participating [2][11]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 5.6% during the last interval, with hospitals, medical research outsourcing, and medical devices leading the gains. Notably, the stock of Sanbo Brain Science surged by 63.53%, while *ST Changyao saw a decline of 44.9% [7][10]. - The report provides detailed performance metrics for various sub-sectors, with hospitals showing a 12.95% increase, medical research outsourcing at 9.25%, and medical devices at 7.96% [8][9]. Industry News and Key Company Announcements - On January 7, eight departments jointly issued the "AI + Manufacturing" action plan, marking AI drug development and medical supply chain intelligence as national priorities [11]. - Notable company announcements include: - Yilian Bio's exclusive licensing agreement with Roche for the YL201 project, which includes a $570 million upfront payment [11]. - Merck's discussions to acquire Revolution Medicines for $28 billion to $32 billion [11]. - Structure Therapeutics' agreement with Roche and Genentech for a non-exclusive patent license, resulting in a $100 million upfront payment [11][12]. - Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion [14].

Core Viewpoint - Walmart is experiencing a pre-market increase of 2.6%, reaching $117.5, potentially setting a new historical high, driven by the announcement of AI shopping assistants in collaboration with major retailers like Google, Shopify, and Wayfair [1] Group 1: AI Integration in Retail - Google has announced partnerships with Walmart and other large retailers to transition from traditional search methods to AI-driven shopping experiences, marking a significant transformation in the retail industry [1] - The collaboration signifies a shift towards AI agents dominating the commercial landscape, indicating the next major change in retail [1] Group 2: Market Position and Index Changes - Walmart will replace AstraZeneca in the Nasdaq 100 index, with the adjustment set to take effect on January 20, 2026 [1]